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Pelvic inﬂammatory disease (PID) is an inﬂammatory pro-
cess elicited by the migration of pathogenic microorganisms
fromthelowertouppergenitaltract.AlthoughPIDisknown
to increase the risk of tubal factor infertility, many other
aspects of this disease remain less well deﬁned. For example,
while PID is often caused by Chlamydia trachomatis or
Neisseria gonorrhoeae infection, frequently, neither of these
bacterial pathogens is isolated from the upper genital tract
of women with PID. This etiologic ambiguity also creates
uncertainty regarding the decision to include antibiotics
eﬀective against genital mycoplasmas and anaerobic vaginal
ﬂora in PID treatment. Moreover, since clinical signs and
laboratory measurements do not precisely identify all PID
cases, and as the accuracy with which imaging modalities
identify upper genital tract inﬂammation is not ﬁrmly
established, PID remains a diagnostic challenge. It is clear,
however, that better understanding of disease pathogenesis,
diagnosis, and treatment is needed to improve the care
provided women with PID, and this issue of Infectious
Diseases in Obstetrics and Gynecology was constructed to
deliver speciﬁc focus on these topics.
Three papers in this issue examine the role of C. tra-
chomatis in PID pathogenesis. The ﬁrst examines ﬁndings
from C. trachomatis infection control programs that have
altered our understanding of the host immune response to
chlamydial infection, and considers implications of these
ﬁndings for prophylactic vaccine development. The second
paper concisely reviews how non-human primate models of
chlamydia infection have improved our understanding of
PID pathogenesis, whilethe third explores a possible associa-
tion between C. trachomatis-speciﬁc humoral immunity and
genital tract inﬂammation. The fourth PID pathogenesis-
focusedpaperisacasereportthatremindsreadersofthelink
between Actinomyces israelii and this disease among women
using intrauterine devices, while the ﬁfth reviews evidence
supporting Mycoplasma genitalium as a cause of PID.
The ﬁve remaining papers in this issue address PID diag-
nosisandtreatment.Theﬁrstdiagnosis-relatedpaperdeﬁnes
a practical approach for the identiﬁcation of women with
PID, while the second tests an algorithm for PID case iden-
tiﬁcation in epidemiological research using administrative
diagnostic codes rather than the more unwieldy medical
record review. The third describes an investigation among a
cohort of women with high prevalence of HIV-1 that found
that the conventional markers of histologic endometritis
(i.e., neutrophils and plasma cells) are, at least in this pop-
ulation, unreliable surrogate markers for laparoscopically
conﬁrmed salpingitis. The fourth paper reviewed existing
literature regarding serologic diagnosis of C. trachomatis
infection in order to construct an algorithm for chlamydial
serologic antibody testing in clinical work-up of the infertile
couple. We close this issue with a comprehensive review
of the antimicrobial therapies currently available for PID
treatment.
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